Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL. D'Antoni ML, et al. Among authors: chang s. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):433-440. doi: 10.1097/QAI.0000000000002888. J Acquir Immune Defic Syndr. 2022. PMID: 34897227 Free PMC article. Clinical Trial.
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES. Bhardwaj N, et al. Among authors: chang s. J Viral Hepat. 2018 Apr;25(4):344-353. doi: 10.1111/jvh.12825. Epub 2017 Dec 28. J Viral Hepat. 2018. PMID: 29112331 Clinical Trial.
HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
Andreatta K, Chang S, Martin R, Acosta R, Daeumer M, Thielen A, Miller MD, White KL. Andreatta K, et al. Among authors: chang s. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e45-e51. doi: 10.1097/QAI.0000000000001757. J Acquir Immune Defic Syndr. 2018. PMID: 29781878 No abstract available.
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. Cathcart AL, et al. Among authors: chang s. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01064-18. doi: 10.1128/AAC.01064-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30038044 Free PMC article.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Andreatta K, et al. Among authors: chang s. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347. J Antimicrob Chemother. 2019. PMID: 31430369 Free PMC article. Clinical Trial.
Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Andreatta K, et al. Among authors: chang s. J Antimicrob Chemother. 2019 Dec 1;74(12):3646-3647. doi: 10.1093/jac/dkz412. J Antimicrob Chemother. 2019. PMID: 31562501 Free PMC article. No abstract available.
21,376 results
You have reached the last available page of results. Please see the User Guide for more information.